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Endogenous Annexin A1 Is a Novel Protective
Determinant in Nonalcoholic Steatohepatitis in Mice
Irene Locatelli,1 Salvatore Sutti,1 Aastha Jindal,1 Marco Vacchiano,1 Cristina Bozzola,1
Chris Reutelingsperger,2 Dennis Kusters,2 Stefania Bena,3 Maurizio Parola,4 Claudia Paternostro,4
Elisabetta Bugianesi,5 Simon McArthur,3 Emanuele Albano,1* and Mauro Perretti3*
Annexin A1 (AnxA1) is an effector of the resolution of inflammation and is highly effec-
tive in terminating acute inflammatory responses. However, its role in chronic settings is
less investigated. Because changes in AnxA1 expression within adipose tissue characterize
obesity in mice and humans, we queried a possible role for AnxA1 in the pathogenesis
of nonalcoholic steatohepatitis (NASH), a disease commonly associated with obesity.
NASH was induced in wild-type (WT) and AnxA1 knockout (AnxA1 KO) C57BL/6
mice by feeding a methionine-choline deficient (MCD) diet up to 8 weeks. In MCD-fed
WT mice, hepatic AnxA1 increased in parallel with progression of liver injury. This
mediator was also detected in liver biopsies from patients with NASH and its degree of
expression inversely correlated with the extent of fibrosis. In both humans and rodents,
AnxA1 production was selectively localized in liver macrophages. NASH in AnxA1 KO
mice was characterized by enhanced lobular inflammation resulting from increased mac-
rophage recruitment and exacerbation of the M1 phenotype. Consistently, in vitro addi-
tion of recombinant AnxA1 to macrophages isolated from NASH livers down-modulated
M1 polarization through stimulation of interleukin-10 production. Furthermore, the
degree of hepatic fibrosis was enhanced in MCD-fed AnxA1 KO mice, an effect associ-
ated with augmented liver production of the profibrotic lectin, galectin-3. Accordingly,
AnxA1 addition to isolated hepatic macrophages reduced galectin-3 expression. Conclu-
sions: Macrophage-derived AnxA1 plays a functional role in modulating hepatic inflam-
mation and fibrogenesis during NASH progression, suggesting the possible use of
AnxA1 analogs for therapeutic control of this disease. (HEPATOLOGY 2014;00:000-000)
N
onalcoholic fatty liver disease (NAFLD) is
regarded as the hepatic feature of so-called
metabolic syndrome (MetS) and is becoming
the most common form of liver injury worldwide as a
result of the diffusion of overweight and obesity.1 In
approximately 10%-20% of patients with NAFLD, the
disease evolves with the development of hepatocellular
damage and lobular inflammation, often leading to
hepatic fibrosis and cirrhosis.1 Available evidence indi-
cates that the mechanisms responsible for the evolution
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of NAFLD to nonalcoholic steatohepatitis (NASH)
may involve lipotoxicity caused by increased circulating
free fatty acids, oxidative damage, and endoplasmic
reticulum stress.2,3 These factors not only cause hepa-
tocyte death, but can also stimulate Kupffer cells to
secrete inflammatory mediators that, in turn, recruit
and activate leucocytes within the liver.2,3 Nonetheless,
the mechanisms responsible for persistence of hepatic
inflammation along with those leading to the evolution
of NASH to fibrosis are still incompletely character-
ized. It is increasingly evident that a failure in the
mechanisms responsible for terminating inflammatory
responses might result in chronic inflammation.4
Resolution of an acute inflammation is orchestrated
by a variety of protein and autacoids that down-
modulate leukocyte recruitment, promote clearance of
tissue leucocytes, and switch macrophage phenotype
favoring tissue healing.5 Among these proresolving
factors, Annexin A1 (AnxA1), also known as
lipocortin-1, is receiving increasing attention. AnxA1
is a 37-kDa calcium-phospholipid–binding protein
highly expressed in myeloid cells and regulated by
glucocorticoids.6 By interacting with its receptor,
formyl peptide receptor 2/lipoxin A4 receptor (FPR2/
ALX), AnxA1 down-regulates the production of
proinflammatory mediators, such as eicosanoids,
nitric oxide, and interleukin (IL)-6, reduces neutro-
phil migration to inflammatory sites, and promotes
the clearance of apoptotic granulocytes.6,7 Further-
more, recent works suggest that endogenous AnxA1
may orchestrate epithelial repair8,9 and even counter-
act the development of lung fibrosis.10
Interest for a possible involvement of AnxA1 in the
evolution of NAFLD originates from the observation
that plasma AnxA1 levels are decreased in obese sub-
jects inversely correlating with body mass index as
well as with the inflammation marker, C-reactive pro-
tein,11 whereas an increased AnxA1 expression was
observed in adipose tissue of obese mice.12 Further-
more, AnxA1 deficiency promotes adiposity and insu-
lin resistance (IR) in Balb/c mice on a high-fat diet
(HFD).12 Because AnxA1-null mice also display inap-
propriate experimental inflammatory responses,7 we
have investigated the possible role of AnxA1 in the
evolution of experimental NASH induced by feeding
mice with a methionine-choline deficient (MCD)
diet.
Material and Methods
Animal and Experimental Protocol. Eight-week-
old male AnxA1 knockout (AnxA1 KO) mice on a
C57BL/6 background and wild-type (WT) animals
were purchased from Charles River Laboratories
(Charles River UK Ltd., Margate, UK) and fed for 4
or 8 weeks with either MCD or control diets (Labora-
torio Dottori Piccioni, Gessate, Italy). In some experi-
ments, mice also received a high-fat (35% w/v) liquid
diet for 12 weeks (see Supporting Information for
details). Experiments were approved by the Italian
Ministry of Health and by the university commission
for animal care following the criteria of the Italian
National Research Council.
Human Specimen Collection and Analysis. Liver
biopsies from 28 consecutive patients with NAFLD or
NASH referring to the Division of Gastro-Hepatology
of the University of Turin (Turin, Italy) in the period
April–November 2011 were analyzed. Specimens were
collected at the time of first diagnosis and processed
for histophatology and extraction of nucleic acid.
Patients were characterized by anthropometric, clinical,
and biochemical data, and liver biopsies were evaluated
for severity of steatohepatitis fibrosis.13 All subjects
gave informed consent to the analysis and the study
was planned according to the guidelines of the local
ethical committee. The major clinical and biochemical
parameters are reported in Supporting Table 1.
Biochemical Analysis. Plasma alanine aminotrans-
ferase (ALT) and liver triglycerides (TGs) were deter-
mined by spectrometric kits supplied by Radim S.p.A.
(Pomezia, Italy) and Sigma Diagnostics (Milano, Italy),
respectively. Circulating tumor necrosis factor alpha
(TNF-a) and liver IL-12 levels were evaluated by com-
mercial enzyme-linked immunosorbent assay (ELISA)
kits supplied by Peprotech (Milano, Italy) and R&D
Systems (Abingdon, UK), respectively.
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Histology and Immunohistochemistry. Lobular
inflammation was scored blind, according to Kleiner
et al.,13 in hematoxilin and eosin (H&E)-stained sec-
tions. Necroinflammatory foci and apoptotic cells were
counted as reported previously.14 Liver macrophages and
activated hepatic stellate cells (HSCs) were evidenced in
formalin-fixed sections using, respectively, anti-mouse
F4/80 or anti-human CD68 (eBioscience, San Diego
CA) and a-smooth muscle actin (a-SMA) polyclonal
antibodies (Abs; Labvision; Bio-Optica SpA, Milan, Italy)
in combination with peroxidase-linked goat anti-rat
immunoglobulin G (IgG) or horseradish peroxidase
polymer kit (Biocare Medical, Concord, CA). AnxA1,
FPR2/ALX, and galectin-3 were detected using specific
Abs from Zymed Laboratories-Invitrogen (Carlsbad,
CA), Santa Cruz Biotechnology (Dallas, TX), and R&D
Systems (Minneapolis, MN), respectively.
Real-Time Polymerase Chain Reaction Analyses.
Liver RNA was retrotranscripted with a High Capacity
complementary DNA (cDNA) Reverse Transcription Kit
(Applied Biosystems Italia, Monza, Italy). Real-time
polymerase chain reaction (RT-PCR) was performed in
a Techne TC-312 termalcycler (TecneInc, Burlington,
NJ) using TaqMan Gene Expression Master Mix and
TaqMan Gene Expression probes for mouse TNF-a, IL-
12p40, IL-23p19, IL-10, chemokine (C-C motif) ligand
2 (CCL2), C-C chemokine receptor type 2 (CCR2),
inducible nitric oxide synthase (iNOS), arginase-1, mac-
rophage galactose N-acetyl-galactosamine-specific lectin-1
(MGL-1), AnxA1, Fpr2/3 (orthologs of human FPR2/
ALX),14 galectin-3, a1-procollagen, transforming growth
factor beta 1 (TGF-b1), a-SMA, tissue inhibitor of
metalloproteinase-1 (TIMP-1), matrix metalloproteinase
(MMP)-9, MMP-13, and b-actin (Applied Biosystems
Italia, Monza, Italy). All samples were run in duplicate,
and the relative gene expression calculated as 22DCt is
expressed as fold increase over control samples. Human
sample analysis was performed using SsoFast EvaGreen
Supermix (Bio-Rad, Hercules, CA), following the manu-
facturer’s instructions. The sequence of primers used
was: sense, 50-GCAGG CCTGGTTTATTGAAA-30;
reverse, 50-GCTGTG CATTGTTTCGCTTA-30. Values
were normalized to those of b-actin and are expressed
by using the comparative 2DDCt method.
AnxA1 Recombinant Protein Purification. cDNA
of human AnxA1 carrying a cleavable N-terminal
poly-His tag was expressed in Escherichia coli and puri-
fied as previously reported.9 Purity of recombinant
AnxA1, as assesed by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis and matrix-assisted laser
desorption/ionization dual time-of-flight mass spec-
trometry, was >95%.
Isolation and Purification of Liver Macrophages.
Macrophages were purified from livers of either controls
or 4-week MCD-fed mice, as previously described.15
Cell purity was above 80%, as determined by flow
cytometry (FCM), after immunostaining for CD45 and
F4/80. Cells were incubated overnight with AnxA1 (100
nM) in the presence or absence of the p38 mitogen-
activated protein kinase (p38MAPK) inhibitor,
SB203880 (10 lM; Sigma-Aldrich, Milan, Italy) and
processed for messenger RNA (mRNA) extraction, as
outlined above. In some experiments, liver nonparenchy-
mal cells were separated on a Ficoll density gradient,
stained with fluorochrome-conjugated Abs for CD45,
F4/80, and IL-10 (eBiosciences, San Diego CA), and
analyzed with a FACScalibur (Becton Dickinson, Frank-
lin Lakes, NJ) flow cytometer. Unspecific immunoglobu-
lin binding was blocked by incubation with
decomplemented mouse serum. AnxA1-producing cells
were detected using a polyclonal anti-AnxA1 rabbit anti-
serum (Millipore, Temecula, CA) and phycoerythrin-
conjugated anti-rabbit IgG (Sigma-Aldrich).
Western Blotting. Liver fragments were homoge-
nized in ice-cold lysis buffer, as previously reported,13
and protein extracts (100 mg) were electrophoresed on
a 10% SDS-polyacrylamide gel. Nitrocellulose mem-
branes probed with monoclonal Abs against mouse
AnxA1 and galectin-3 were revealed with Western
Lightning Chemiluminescence Reagent Plus (ECL;
Perkin-Elmer, Boston, MA) using the VersaDoc 3000
quantitative imaging system and Quantity One soft-
ware (Bio-Rad).
Statistical Analysis. Statistical analyses were per-
formed by SPSS statistical software (SPSS, Inc., Chi-
cago IL, USA) using the one-way analysis of variance
(ANOVA) test with Tukey’s correction for multiple
comparisons or Kruskal-Wallis’ test for nonparametric
values. Significance was taken at the 5% level. Normal-
ity distribution was preliminarily assessed by
Kolmogorov-Smirnov’s test.
Results
The Progression of NASH Is Associated With a
Stimulation in Liver AnxA1. AnxA1 was expressed
at low extent in livers of na€ıve mice, whereas both
mRNA and protein content increased in a time-
dependent manner in livers of animals with NASH
induced by feeding the MCD diet (Fig. 1). AnxA1
expression in NASH livers was selectively localized in
enlarged vacuolized mononucleated cells that were pos-
itive for the macrophage marker, F4/80 (Fig. 1). Dou-
ble staining of frozen liver sections with an anti-AnxA1
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Fig. 1. Hepatic AnxA1 expression in mice with NASH. Mice were fed an MCD diet over an 8-week period. (A and B) AnxA1 mRNA and protein
levels, as measured by RT-PCR and western blotting analyses, respectively, in liver extracts of mice receiving control or MCD diet. Hepatic mRNA
data are expressed as fold increase over control values after normalization to the b-actin gene. Data are from 8-12 animals per group; boxes
include the values within 25th and 75th percentile, whereas horizontal bars represent the medians. The extremities of the vertical bars (10th-
90th percentile) comprise 80% of the values. Statistical differences were assessed by one-way ANOVA test with Tukey’s correction for multiple
comparisons. (C and D) Localization of AnxA1 expression by IHC in liver of MCD-fed animals (magnification, 4003). (E) Detection of macro-
phages positive for F4/80 immunostaining (magnification, 4003). (F) Colocalization of AnxA1 in macrophages containing lipid vacuoles was evi-
denced by double staining of frozen liver sections with the lipid dye, Oil Red O (red), and anti-AnxA1 Ab (green immunofluorescence;
magnification, 4003). Cell nuclei were courterstained with 40,6-diamidino-2-phenylindole. Images are representative of 3-4 distinct samples.
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Ab and the lipid dye Oil Red O confirmed that
AnxA1-positive macrophages contained lipid droplets
(Fig. 1), likely derived from the scavenging of dying fat-
laden hepatocytes. Histological analysis indicated that
AnxA1-producing cells were more frequent in livers of
animals with advanced NASH (8 weeks on the MCD
diet) than in those with less-severe steatohepatitis (4
weeks of treatments; 4.76 0.5 vs. 2.86 0.8 cells/high-
magnification field [hmf]; P5 0.03). Animals with
advanced NASH also showed an increase in hepatic
mRNA content of the AnxA1 receptor, Fpr2/3, and
presence of Fpr2/3-expressing cells in liver sections
(Supporting Fig. 1). Although AnxA1 up-regulation
paralleled the severity of NASH, an increased expression
of AnxA1 was already evident along with early signs of
inflammation in livers with only steatosis induced by
feeding mice for 12 weeks with an HFD that caused
obesity and IR (Supporting Fig. 2).
In line with the results obtained in rodents, liver
biopsy sections from subjects with NASH showed an
increased prevalence of CD681 macrophages producing
AnxA1 (Fig. 2). A further evaluation of AnxA1 mRNA
levels in 28 liver biopsies from NAFLD/NASH patients
evidenced that AnxA1 expression was not related to the
degree of IR or severity of liver injury (not shown), but
inversely correlated with extension of fibrosis
(r520.59; P< 0.003). In particular, AnxA1 mRNA
was significantly lower in subjects with bridging fibrosis,
as compared to those with mild/moderate pericentral or
-portal fibrosis or without fibrosis (Fig. 2).
AnxA1 Deficiency Stimulates Hepatic Inflamma-
tion in Advanced NASH. To further make insights
on the role of AnxA1 in the evolution of NASH,
AnxA1 KO mice were administered the MCD diet.
Livers of AnxA1 KO mice on a control diet displayed
normal histological appearance apart from the sporadic
presence of monocyte infiltration (Fig. 3). Upon feed-
ing the MCD diet for either 4 and 8 weeks, liver TGs,
transaminase release, and the prevalence of apoptotic
cells (4.26 1.7 vs. 3.46 0.6; P5 0.33) and necrotic
foci (4.56 1.4 vs. 3.86 1.9; P5 0.43) in AnxA1 KO
and WT mice were not statistically different (Fig. 3).
However, already after 4 weeks on MCD diet, semi-
quantitative scores of lobular inflammation were higher
in AnxA1 KO mice (2.26 0.4 vs. 1.46 0.5; n5 12;
P5 0.01) and remained elevated by extending the
treatment to 8 weeks (2.46 0.6 vs. 1.66 0.5; n5 12;
P5 0.03). At this time point, NASH in AnxA1 KO
mice was characterized by diffuse inflammatory foci
containing mononucleated cells and by marked up-
regulation in liver and circulating levels of TNF-a
(Fig. 3). Accordingly, 8-week MCD-fed AnxA1 KO
mice had higher mRNA for the chemokine, CCL2,
and its receptor, CCR2, together with an elevated
number of hepatic macrophages, when compared to
paired WT animals (Fig. 4).
Characterization of AnxA1 Effect on Hepatic
Macrophages Functions. To further characterize the
molecular and cellular events modulated by AnxA1,
hepatic macrophage functions were investigated. In
WT mice, NASH progression is characterized by a
biphasic change in liver expression of macrophage M1
activation markers, including iNOS, IL-12p40, and
IL-23p19. These were elevated after 4 weeks on the
MCD diet and declined thereafter (Fig. 4). In these
animals, individual AnxA1 mRNAs inversely correlated
with those of iNOS (r520.62; P5 0.01), IL-12p40
(r520.48; P5 0.03), and IL-23p19 (r520.62;
P5 0.03), pointing to the possible contribution of
endogenous AnxA1 in down-regulating macrophage
M1 responses during disease progression. Supporting
this view, AnxA1 KO mice receiving the MCD diet
for 8 weeks did not show any decline in iNOS, IL-
12p40, and IL-23p19 liver mRNAs: These markers
were instead approximately 2-3 fold higher than those
measured in WT animals (Fig. 4). In the same vein,
hepatic IL-12 protein content was significantly
enhanced in AnxA1-KO mice (Fig. 4).
Recent reports have linked the proresolving properties
of AnxA1 with a stimulation of IL-10 production
through a p38MAPK signaling path, together with
induction of M2 polarization.16,17 FCM analysis of mac-
rophages isolated from livers of WTmice fed for 4 weeks
with the MCD diet showed that AnxA1-expressing F4/
801 cells had a higher IL-10 content than those with
AnxA1 negatives (Fig. 5). Furthermore, incubation with
AnxA1 of macrophages isolated from NASH livers
halved the expression of iNOS and IL-12p40 without
affecting that of the M2 markers, arginase-1 and MGL-
1/CD301 (Fig. 5). In AnxA1-treated macrophages, sup-
pression of M1 activation was associated with a 2-fold
increase in IL-10 mRNA (Fig. 5). Moreover, addition of
the p38MAPK inhibitor, SB203880, reverted both
AnxA1-induced IL-10 stimulation and down-modulation
of iNOS and IL-12p40 (Fig. 5). Interestingly, macro-
phage incubation with AnxA1 also significantly lowered
CCL2 and CCR2 mRNA levels in a p38MAPK-
dependent manner (Fig. 5), suggesting the potential
capacity of AnxA1 to influence hepatic monocytic
recruitment through CCL2 and CCR2 signalling.
AnxA1 Deficiency Stimulates the Fibrogenic Evo-
lution of NASH. The data obtained in the patients
with NAFLD/NASH indicate an inverse association
between liver expression of AnxA1 and the extension
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of hepatic fibrosis. By investigating the effects of
AnxA1 deficiency on the fibrogenic evolution of exper-
imental NASH, we observed that the fibrosis markers,
pro-collagen-1a, a-SMA, and TIMP-1, were higher in
MCD-fed AnxA1 KO mice than in WT animals
(Fig. 6). Hepatic collagen deposition, as evidenced by
Sirius Red staining, and a-SMA-positive activated
HSCs (4.36 0.9 vs. 20.36 3.8 cells/hmf; P< 0.005)
Fig. 2. AnxA1 expression in human livers with or without NASH. AnxA1 detection by IHC in liver specimens from control individuals (A) and
NASH patients (B). CD68-positive macrophages (from the same NASH patient; C) (magnification, 4003). Control liver samples refer to surgical
resections for hepatic metastasis of colon carcinoma. (D) AnxA1 mRNA was measured in liver biopsies of 28 NASH patients using RT-PCR and
normalized to that of b-actin. Boxes include the values within 25th and 75th percentile, whereas horizontal bars represent the medians. The
extremities of the vertical bars (10th-90th percentile) comprise 80% of the values. The extent of liver fibrosis was scored according to Kleiner
et al.12
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Fig. 3. AnxA1 deficiency promotes steatohepatitis in mice with NASH. WT and AnxA1 KO C57BL/6 mice were fed the MCD diet up to 8 weeks.
(A-D) Liver histology was evaluated in H&E-stained sections from control or MCD-fed animals (magnification, 2003). (E-G) NASH severity was
assessed by circulating ALT release, hepatic TG content and liver TNF-a mRNA levels, measured by RT-PCR and expressed as fold increase over
control values after normalization to the b-actin gene. (H) Circulating TNF-a levels were determined by ELISA. Values refer to 6-8 animals per
group; boxes include the values within 25th and 75th percentile, whereas horizontal bars represent the medians. The extremities of the vertical
bars (10th-90th percentile) comprise 80% of the values. Statistical differences were assessed by one-way ANOVA test with Tukey’s correction for
multiple comparisons.
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were also more evident in AnxA1 KO mice with
NASH. These latter a-SMA-positive HSCs were often
surrounded by cell clusters containing F4/80-positive
mononucleated cells (Fig. 6). Stimulation of liver
fibrosis in AnxA1-KO animals was unrelated to regula-
tion of hepatic TGF-b1 or of MMP-9 and MMP-13
(Supporting Fig. 3), suggesting that additional factors
may contribute to the profibrogenic evolution of
NASH.
The beta-galactoside-binding lectin, galectin-3, can
direct myofibroblast activation in fibrotic livers and
has been associated with the pathogenesis of
NASH.18,19 In our experiments, liver galectin-3 expres-
sion was up-regulated in WT mice with advanced
Fig. 4. AnxA1 deficiency promotes liver macrophage recruitment and activation. WT and AnxA1 KO C57BL/6 mice were fed the MCD diet up
to 8 weeks. (A) Macrophage counts after immunostaining with anti-F4/80 Ab. (B-F) Liver mRNA levels for CCL2, CCR2, and the macrophage M1
activation markers, IL-12p40, IL23p19, and iNOS, as measured by RT-PCR. Data are expressed as fold increase over control values after normal-
ization to the b-actin gene. (G) Liver IL-12 protein content as determined in the same animals. In all cases, values refer to 8-12 animals per
group and boxes include the values within 25th and 75th percentile, whereas horizontal bars represent the medians. The extremities of the verti-
cal bars (10th-90th percentile) comprise 80% of the values. Statistical differences were assessed by one-way ANOVA test with Tukey’s correction
for multiple comparisons.
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NASH and even more in AnxA1 KO mice which, at
the 8-week time point had a hepatic content of
galectin-3 2-fold higher than WTmice (Fig. 7). In line
with these ex vivo data, in vitro experiments showed
that AnxA1-mediated signals effectively down-
modulated galectin-3 expression in macrophages
Fig. 5. AnxA1 regulates macrophage functions through stimulation of IL-10 production. Hepatic macrophages were isolated from livers of either
control or 8-week MCD-fed mice. (A) F4/80-positive cells were analyzed by FCM for the coexpression of AnxA1 and IL-10 or MCD-fed mice.
(B) Macrophages isolated from livers of MCD-fed mice were incubated in vitro with or without recombinant AnxA1 (100 nM) and the p38MAPK
inhibitor, SB203880 (SB; 10 lM), and subsequently analyzed for expression of IL-10 mRNA (B). (C and D) RT-PCR analyses for other markers,
including M1 (iNOS and IL-12p40) and (F and G) M2 activation markers (arginase-1 and MGL-1/CD301), as well as (E and H) CCL2 or CCR2.
Values refer to four to five different cell preparations and are presented as mean6 standard deviation. Statistical differences were assessed by
one-way ANOVA test with Tukey’s correction for multiple comparisons.
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Fig. 6. AnxA1 deficiency promotes hepatic fibrosis in mice with NASH. WT and AnxA1 KO C57BL/6 mice were fed the MCD diet for 8 weeks.
(A-C) Liver mRNA levels for pro-collagen-1a, a-SMA, and TIMP-1, as measured by RT-PCR, and are expressed as fold increase over control values
after normalization to the b-actin gene. Values refer to 6-8 animals per group and boxes include the values within 25th and 75th percentile,
whereas horizontal bars represent the medians. The extremities of the vertical bars (10th-90th percentile) comprise 80% of the values. Statistical
differences were assessed by one-way ANOVA test with Tukey’s correction for multiple comparisons. (D and F) Collagen deposition as detected
by Sirius Red staining in representative liver sections from 8-week MCD diet in WT and AnxA1 KO mice. (E and G) Activated HSCs expressing
a-SMA (magnification, 4003 and 2003). Enlargement shows a-SMA-positive HSCs surrounded by collagen fibers forming cell foci with mono-
nucleated cells. (H) These latter were stained by the macrophage marker, F4/80 (magnification, 6003).
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Fig. 7. AnxA1 regulates galectin-3 production in livers of mice with NASH. WT and AnxA1 KO C57BL/6 mice were fed the MCD diet for 8
weeks. (A and B) Galectin-3 mRNA (boxes and whiskers) and protein levels (mean6 standard deviation) were measured by RT-PCR and western
blotting, respectively. Data are from 6-8 mice per group and statistical differences were assessed by one-way ANOVA test with Tukey’s correction
for multiple comparisons. (C) Macrophages isolated from livers of control (Cont) or 4-week MCD-fed mice were incubated with or without
recombinant AnxA1 (100 nM) and the p38MAPK inhibitor, SB203880 (SB; 10 lM), for 16 hours before quantification of galectin-3 mRNA.
(D and E) Liver galectin-3 expression by IHC in MCD-fed animals (magnification, 4003). Enlargement shows cell foci containing galectin-3 mac-
rophages and HSCs.
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isolated from NASH livers (Fig. 7). Conversely, addi-
tion of AnxA1 to the same macrophage preparations
did not affect TGF-b1 mRNA (not shown). At immu-
nohistochemistry (IHC), galectin-3 production was
particularly evident in the macrophage foci mentioned
above (Fig. 7). These galectin-3-positive foci were
more frequent in AnxA1 KO livers (2.86 0.8 vs.
4.66 0.5 cell foci/hmf; P< 0.03). Moreover, in these
latter, the presence of HSCs along with the macro-
phages is associated with abundant collagen fibers sur-
rounding the foci (Fig. 6).
Discussion
Growing evidence points to the importance of
AnxA1 in the modulation of anti-inflammatory and
proresolving responses in rodent models of acute
inflammation.6,7 We now identify novel modulatory
functions of AnxA1 in livers of mice with chronic stea-
tohepatitis induced by feeding with an MCD diet.
Coupled to the translational data with human NASH,
and a series of mechanistic readouts in human and
mouse macrophage, we unveil an AnxA1-centerd path-
way engaged by the host for liver protection.
In experimental models of NAFLD/NASH, up-
regulation of AnxA1 is already evident in fatty livers
and further increases with disease progression specifi-
cally involving macrophages containing intracytoplas-
matic lipid droplets. The origin of these macrophages
has not been characterized in detail, though our pre-
liminary data indicate that these cells express, to a low
extent, the monocyte marker, Ly6C,20 suggesting that
they might derive from inflammatory macrophages
that had undergone phenotypic changes after scaveng-
ing dying fat-laden hepatocytes. Interestingly, macro-
phages are also the predominant source of AnxA1 in
adipose tissue of obese mice,12 suggesting that, during
MetS, AnxA1 up-regulation might be a common
response in macrophages, irrespective of their tissue
location. In this study, the increase in liver AnxA1 was
observed in both an experimental model of NAFLD
based on mice feeding with an HFD as well as in
NASH induced by the MCD diet. We are aware that
the MCD model does not reproduce some of the key
features of human diseases, such as obesity and IR.
However, it was preferred for characterizing the role of
AnxA1 in NASH evolution because it causes extensive
steatohepatitis rapidly progressing to fibrosis.21
In line with the homeostatic properties of AnxA1,
we observed that AnxA1 deficiency promotes lobular
inflammation in MCD-fed mice, particularly in ani-
mals with more advanced NASH, as observed after 8
weeks of treatment. The mechanisms behind the
inflammatory phenotype appear related to the direct
action of AnxA1 on the macrophages. Indeed, in livers
of WT animals with advanced NASH, higher AnxA1
expression is associated with a down-modulation of
the macrophage M1 phenotype. Such an effect is
absent in AnxA1 KO mice that display instead elevated
expression of iNOS, IL-12p40, and IL-23p19 gene
products. Moreover, the in vitro addition of recombi-
nant AnxA1 reduced M1 marker expression in macro-
phages isolated from NASH livers by more than 50%.
Altogether, these results suggest that macrophage-
derived AnxA1 represents an autocrine/paracrine loop
that suppresses, at least in part, proinflammatory M1
responses. This new notion is consistent with data
indicating a central role for AnxA1 in the down-
modulation of TNF-a and IL-6 production by macro-
phages exposed to glucocorticoids.6,22
The homeostatic functions of AnxA1 are mediated
by FPR2/ALX, a G-protein-coupled receptor that is
shared with other proresolving lipid mediators, includ-
ing lipoxin A4 and resolvin D1,
23,24 as well as with
the proinflammatory protein, serum amyloid A, and
cathelicidin LL-37.25,26 We observed that in vivo mac-
rophage responses to endogenous AnxA1 become
appreciable when FPR2/ALX is overexpressed in
advaced NASH. Recently, Cooray et al. unveiled an
AnxA1-specific FRP2/ALX proresolving signal pathway
involving p38MAPK, MAPKAPK1/2, and heat shock
protein 27, leading to generation of IL-10.17 In our
experiments with isolated macrophages from NASH
livers, down-modulation of iNOS and IL-12p40 is
associated with a 2-fold rise in IL-10 expression;
importantly, pharmacological inhibition of p38MAPK
affects, in opposite ways, AnxA1-induced IL-10 stimu-
lation and suppression of M1 polarization. The
importance of IL-10 in mediating AnxA1 action is
consistent with the observation that an N-terminal
AnxA1-derived peptide (Ac1-25) fails to exert
anti-inflammatory activity in IL-10-deficient mice.27
Collectively, and complementing a recent study,17 these
data indicate that AnxA1 can down-regulate macro-
phage M1-responses through an FPR2/ALX dimeriza-
tion signal centerd on p38 and ultimately leading to
IL-10 generation. These new data provide pathophysio-
logical relevance to this novel network of resolution,
formed by AnxA1/FPR2 and IL-10, and operative in
NASH livers to limit and delay disease progression.
In addition to modulation of proinflammatory
activity of macrophages, AnxA1 might also regulate
liver recruitment of monocytes by controlling the
expression of the CCL2/CCR2 pair. Indeed, CCR2 is
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one of the genes more extensively down-regulated in
human monocytes exposed to Ac1-25 AnxA1-derived
peptide.28 However, differently from that reported by
Lange et al.,28 in our hands, the p38 inhibitor,
SB203880, effectively reverted the effect of AnxA1 on
CCR2 regulation in mice macrophages. Thus far,
AnxA1 has been implicated in reducing granulocyte-
tissue infiltration by blocking neutrophil-endothelial
interactions and accelerating neutrophil apoptosis.6,7
Neutrophil infiltration is not relevant in the pathoge-
nesis of NASH, whereas macrophages and lymphocytes
are the predominant inflammatory cells.29 Thus, our
data point to the possibility that, during chronic
inflammation, AnxA1 might also control the recruit-
ment of monocytes. The capacity of AnxA1 to inter-
fere with the CCL2/CCR2 axis might be particularly
relevant in relation to the evolution of steatohepatitis,
because CCR2 deficiency and CCR2 antagonism
ameliorate liver injury and fibrosis in experimental
NASH.30,31 Possibly unrelated to the IL-10 effect dis-
cussed above, AnxA1-mediated CCR2 down-regulation
provides further mechanistic support to the
“protective” role played by this mediator.
NASH is increasingly recognized as an important
cause for liver fibrosis, and approximately 15% of
NASH patients progress to advanced fibrosis/cirrhosis.1
However, the factors responsible for the large interindi-
vidual variability in development of fibrosis are still
poorly characterized. Here, we report that (1) AnxA1-
expressing macrophages are evident in liver biopsies of
patients suffering from NAFLD/NASH and (2)
AnxA1 mRNA levels in these patients inversely corre-
late with the severity of fibrosis. In line with these
clinical data, experimental NASH in AnxA1-KO mice
is characterized by increased liver fibrosis, suggesting
that AnxA1 can prevent the fibrogenic evolution of
NASH. Besides the immune-mediated events discussed
above, this effect might involve modulation of
galectin-3 expression. Galectin-3 is a member of the
galectin family, a group of lectins that participates in
the regulation of cell adhesion, proliferation and sur-
vival, as well as in the modulation of tissue inflamma-
tion and fibrosis.32 In acutely injured livers, galectin-3
is mainly produced by macrophages and sustains M1
activation in models of acetaminophen- and
concanavalin-A-induced hepatitis.33,34 Conversely, in
rodent and human livers with fibrosis, galectin-3 is
also expressed by activated a-SMA-positive HSCs and
regulates their profibrogenic activity.19,35 Recent stud-
ies have implicated galectin-3 in the pathogenesis of
NASH, although with controversial results, because
galectin-3-deficient mice show either protection18 or
increased disease severity36,37 in relation to an
impaired glucose metabolism and an increased suscep-
tibility to obesity and systemic inflammation.38,39 In
our hands, an increase in liver galectin-3 characterizes
advanced NASH in MCD-fed mice and galectin-3
appears susceptible to modulation by AnxA1. More-
over, the worsening of fibrosis quantified in MCD-fed
AnxA1 KO mice associates with a further up-
regulation in galectin-3 levels. In these latter, hepatic
fibrosis is characterized by the diffuse presence of cell
clusters composed of galectin-3-expressing macro-
phages and activated HSCs, whereas liver collagen
deposition is particularly evident around these clusters,
supporting a specific role of galectin-3 in stimulating
profibrogenetic cell-to-cell interactions. Consistently,
galectin-3 secretion by macrophages has been impli-
cated in the promotion of renal and vascular fibro-
sis,40,41 whereas genetic deletion or inhibition of
galectin-3 attenuates HSC activation and hepatic colla-
gen deposition in CCl4
2 or tioacetamide-treated
mice19,42 and ameliorated inflammation and fibrosis in
experimental NASH.43
Altogether, these results afford a novel functional
role for AnxA1 in NASH progression, a property
mediated through a control of hepatic inflammation
and fibrogenesis as well as uneven modulation of
galectin-3 and IL-10, leading to a reduced macrophage
M1 response. It is plausible that strategies aiming at
increasing hepatic AnxA1 expression, or the develop-
ment of AnxA1 analogs,44 might have a potential for
therapeutic control on NASH evolution.
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